We observed a much more enhanced killing effect of the ABT263 + AXIT combination compared with the single drug treatment in HT29 KRAS-mutant cells (Figure 1D), suggesting that KRAS-mutant colon cancer cells may be selectively sensitive to the ABT263 + AXIT combination. Here, KRAS is linked to malignant colon neoplasm.